Treatment Patterns, Adverse Events, and Clinical Outcomes with Steroidal Mineralocorticoid Receptor Antagonists: A Retrospective Analysis of Administrative Claims Data (RELICS) [0.03%]
矿化甾体糖皮质激素受体拮抗剂的治疗模式，不良反应和临床结果：行政索赔数据的回顾性分析(RELICS)
Emma L Richard,Nihar R Desai,Vincent J Willey et al.
Emma L Richard et al.
Purpose: This study aimed to describe the characteristics, treatment patterns, adverse events (AEs), and clinical outcomes of patients starting steroidal mineralocorticoid receptor antagonists (sMRAs) in real-world settin...
Validation of Mortality Data Sources Compared to the National Death Index in the Healthcare Integrated Research Database [0.03%]
基于HealthCare集成研究数据库的死亡记录验证分析
Aziza Jamal-Allial,Todd Sponholtz,Shiva K Vojjala et al.
Aziza Jamal-Allial et al.
Background: The National Death Index (NDI) is the gold standard for mortality data in the United States (US) but has a time lag and can be operationally intensive. This validation study assesses the accuracy of various mo...
Review of Challenges in Performing Real-World Evidence Studies for Nonprescription Products [0.03%]
非处方药品真实世界研究的挑战性回顾分析
Christian Maihöfner,Theresa Mallick-Searle,Jan Vollert et al.
Christian Maihöfner et al.
In recent years, regulatory authorities have signaled a willingness to consider real-world evidence (RWE) data to support applications for new claims and indications for pharmaceuticals. Historically, RWE studies have been the domain of pre...
Measuring Diagnostic Quality: The Capacity of Routinely Collected Data and Applications to Chronic Respiratory Disease [0.03%]
基于常规收集数据的诊断质量评估及其在慢性呼吸疾病中的应用
Rachael Mountain,Timothy Gatheral,Patrick Haslam et al.
Rachael Mountain et al.
Detection of Patient-Level Immunotherapy-Related Adverse Events (irAEs) from Clinical Narratives of Electronic Health Records: A High-Sensitivity Artificial Intelligence Model [0.03%]
基于电子健康记录临床叙述检测免疫治疗相关不良事件的患者级人工智能高灵敏度模型
Md Muntasir Zitu,Margaret E Gatti-Mays,Kai C Johnson et al.
Md Muntasir Zitu et al.
Purpose: We developed an artificial intelligence (AI) model to detect immunotherapy -related adverse events (irAEs) from clinical narratives of electronic health records (EHRs) at the patient level. ...
Validation and Final Results from the First Cardiac Lead Post-Approval Study Using Real-World Data [0.03%]
基于真实世界数据的心脏导线首次上市后研究的验证和最终结果
Steven Mullane,Jacob B Hicks,Kazi Sharmin et al.
Steven Mullane et al.
Background: As part of Electrophysiology Predictable and Sustainable Implementation of National Registries (EP PASSION), a multi-stakeholder collaboration between the US Food and Drug Administration (FDA), academic and so...
Preserved Ratio Impaired Spirometry in US Primary Care Patients Diagnosed with Chronic Obstructive Pulmonary Disease [0.03%]
慢性阻塞性肺病患者气流阻塞比例与 spirometry 检测结果受损之间的关系研究
Alexander Evans,Yasir Tarabichi,Wilson D Pace et al.
Alexander Evans et al.
Background: Preserved ratio impaired spirometry (PRISm) represents a population with spirometry results that do not meet standardized COPD obstruction criteria, yet present with high respiratory symptom burden and might b...
Patient Characteristics, Management, and Outcomes of Adult Asthma in a Singapore Population: Data from the SDG-CARE Asthma Registry [0.03%]
新加坡某人群成年人哮喘患者的临床特征、管理及结局：来自SDG-CARE哮喘登记册的数据
Mariko Siyue Koh,Sean Shao Wei Lam,Xiaomeng Xu et al.
Mariko Siyue Koh et al.
Purpose: Patients with asthma in Singapore often have complex patient journeys, with diagnosis and management across various primary and speciality care settings. Real-world population health data is needed to identify ca...
Improving the Transparency and Replicability of Consensus Methods: Respiratory Medicine as a Case Example [0.03%]
以呼吸系统疾病为例提高共识方法的透明度和可重复性
Mark J Rolfe,Christopher C Winchester,Alison Chisholm et al.
Mark J Rolfe et al.
Non-Alcoholic Steatohepatitis Patient Characterization and Real-World Management Approaches in Italy [0.03%]
意大利非酒精性脂肪肝病患者特征及现实世界的管理方法
Elisabetta Bugianesi,Luca Miele,Giovanna Donnarumma et al.
Elisabetta Bugianesi et al.
Background: Although the estimated prevalence of non-alcoholic steatohepatitis (NASH) in Italy is 4-6%, little is known about patient characteristics and care pathways. ...